Article History

Received 2 April 2016
Received in revised form 12 April 2016
Accepted 28 April 2016
Available online 30 April 2016

Keywords

Diabetes mellitus, TCF7L2, Ipomoea sepiaria, GC-MS, bioactive compound, molecular docking.

MOLECULAR DOCKING IDENTIFICATION OF BEST DRUG MOLECULE FROM IPOMOEA SEPIARIA (KOENIG EX. ROXB) LEAVES AGAINST TYPE 2 DIABETES MELLITUS

Senthil Janarthanan1*, Rameashkannan Madurai Vardharajulu1 and Mani Panagal2

1Department of Medicinal Plant Biotechnology, Sharmila Institute of Medicinal Products Research Academy, Thanjavur, Tamilnadu, India.

2Department of Biotechnology, Annai College of Arts and Science, Kumbakonam, Tamilnadu, India.

*Corresponding author : senjana25@gmail.com

ABSTRACT: Diabetes Mellitus (DM) is a chronic endocrine disorder caused by inherited and acquired deficiency in insulin production by pancreas. The reduced insulin activity results in hyperglycemia and abnormalities in carbohydrate, protein and fat metabolism. Type II diabetes is one of the major life threatening disease worldwide and number of cases are increasing every year. Many research works are in progress to control the disease by targeting its enzymes or proteins. Transcription Factor 7 - Like 2 (TCF7L2) gene is responsible for type 2 diabetes. Ipomoea sepiaria (Koenig Ex. Roxb) is found to be one of the best medicinal plants for diabetes mellitus. This medicinal plant leaves contains rich source of many bioactive compounds that act against diabetes mellitus. In the present investigation, 32 bioactive compounds were identified from Ipomoea sepiaria through Gas Chromatography - Mass Spectrometry (GC-MS) analysis. The compounds identified are tested against TCF7L2 through molecular docking. Out of 32 compounds, 1-Monolinoleoylglycerol trimethylsilyl ether is identified as best bioactive compound against type 2 diabetes based on energy values.

 

Full text article in PDF